Should treatment of low-level rifampicin mono-resistant tuberculosis be different?

BACKGROUND: Rifampicin resistant tuberculosis (RR-TB) was frequently detected in Suriname after the introduction of Xpert MTB/RIF in 2012. Subsequent phenotypic drug-susceptibility testing (DST) was not conclusive at that moment, while RR-TB patients treated with first-line tuberculostatics had good...

Descripción completa

Detalles Bibliográficos
Autores principales: Gopie, F.A., Commiesie, E., Baldi, S., Kamst, M., Kaur, D., de Lange, W.C.M., Pinas, P.S., Stijnberg, D., Wongsokarijo, M., Zijlmans, C.W.R., de Zwaan, R., van Soolingen, D., Vreden, S.G.S., de Vries, G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7869001/
https://www.ncbi.nlm.nih.gov/pubmed/33598570
http://dx.doi.org/10.1016/j.jctube.2021.100222

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7869001/
https://www.ncbi.nlm.nih.gov/pubmed/33598570
http://dx.doi.org/10.1016/j.jctube.2021.100222

Ejemplares similares